• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

不可切除肝细胞癌患者的肝动脉灌注化疗：3年生存率更新

Hepatic arterial infusion chemotherapy in patients with unresectble hepatocellular carcinoma: 3-year survival update.

作者信息

Chen Shiguang, Yu Wenchang, Wang Xiaolong, Liu Weifu

机构信息

Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.

出版信息

Hepat Oncol. 2025 Dec;12(1):2516994. doi: 10.1080/20450923.2025.2516994. Epub 2025 Jun 17.

DOI:10.1080/20450923.2025.2516994
PMID:40528356
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12184121/
Abstract

AIMS

Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin plus raltitrexed showed a promising response rate in patients with unresectable hepatocellular carcinoma (HCC) in a phase 2 trial. Here, we report the updated 3-year survival data after enrollment.

METHODS

In this prospective trial, we enrolled patients with intermediate and advanced unresectable HCC. The treatment was HAIC with raltitrexed plus oxaliplatin.

RESULTS

The objective responses were achieved in 19 (48.7%) of 39 patients in the intention-to-treat population. The median overall survival and progress-free survival were 11.2 and 6.5 months, respectively.

CONCLUSION

The 3-year survival update confirmed the antitumor activity and long-term survival benefit of HAIC with oxaliplatin plus raltitrexed in patients with unresectable HCC.

CLINICAL TRIAL REGISTRATION

www.chictr.org.cn identifier is ChiCTR-OOC-17014182.

摘要

目的

在一项2期试验中，奥沙利铂联合雷替曲塞的肝动脉灌注化疗（HAIC）对不可切除肝细胞癌（HCC）患者显示出有前景的缓解率。在此，我们报告入组后的3年生存更新数据。

方法

在这项前瞻性试验中，我们纳入了中晚期不可切除HCC患者。治疗方案为雷替曲塞联合奥沙利铂的HAIC。

结果

在意向性治疗人群的39例患者中，19例（48.7%）获得客观缓解。中位总生存期和无进展生存期分别为11.2个月和6.5个月。

结论

3年生存更新数据证实了奥沙利铂联合雷替曲塞的HAIC对不可切除HCC患者的抗肿瘤活性和长期生存获益。

临床试验注册

www.chictr.org.cn标识符为ChiCTR-OOC-17014182。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ae8/12184121/419795b78afb/IHEP_A_2516994_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ae8/12184121/a43f866a2c32/IHEP_A_2516994_F0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ae8/12184121/b0e2913c20b9/IHEP_A_2516994_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ae8/12184121/419795b78afb/IHEP_A_2516994_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ae8/12184121/a43f866a2c32/IHEP_A_2516994_F0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ae8/12184121/b0e2913c20b9/IHEP_A_2516994_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ae8/12184121/419795b78afb/IHEP_A_2516994_F0003_C.jpg

相似文献

1
Hepatic arterial infusion chemotherapy in patients with unresectble hepatocellular carcinoma: 3-year survival update.不可切除肝细胞癌患者的肝动脉灌注化疗：3年生存率更新
Hepat Oncol. 2025 Dec;12(1):2516994. doi: 10.1080/20450923.2025.2516994. Epub 2025 Jun 17.
2
The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.伊立替康、奥沙利铂和雷替曲塞用于治疗晚期结直肠癌：系统评价与经济学评估
Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. doi: 10.3310/hta12150.
3
Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis.晚期肝细胞癌患者一线治疗的疗效与安全性：一项系统评价和网状Meta分析
Front Immunol. 2024 Sep 17;15:1430196. doi: 10.3389/fimmu.2024.1430196. eCollection 2024.
4
Sequencing of systemic therapy in unresectable hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis of randomized clinical trials.系统治疗不可切除肝细胞癌的序贯治疗：随机临床试验的系统评价和贝叶斯网络荟萃分析。
Crit Rev Oncol Hematol. 2024 Dec;204:104522. doi: 10.1016/j.critrevonc.2024.104522. Epub 2024 Sep 26.
5
Comparison of the efficacy and safety of TACE-HAIC-MTTs-ICIs and TACE-MTTs-ICIs in the hepatocellular carcinoma: a prognostic analysis based on the dynamic changes of serum AFP.经动脉化疗栓塞-肝动脉灌注化疗-多靶点酪氨酸激酶抑制剂-免疫检查点抑制剂（TACE-HAIC-MTTs-ICIs）与经动脉化疗栓塞-多靶点酪氨酸激酶抑制剂-免疫检查点抑制剂（TACE-MTTs-ICIs）治疗肝细胞癌的疗效和安全性比较：基于血清甲胎蛋白动态变化的预后分析
Int J Surg. 2025 Jun 20. doi: 10.1097/JS9.0000000000002818.
6
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial.托法替布联合贝伐珠单抗对比索拉非尼作为晚期肝细胞癌一线治疗的疗效（HEPATORCH）：一项随机、开放标签的3期试验
Lancet Gastroenterol Hepatol. 2025 Jul;10(7):658-670. doi: 10.1016/S2468-1253(25)00059-7. Epub 2025 May 20.
7
Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.不同经动脉栓塞疗法单独或联合局部消融或辅助全身治疗对不可切除肝细胞癌的比较疗效：一项随机对照试验的网状Meta分析
PLoS One. 2017 Sep 21;12(9):e0184597. doi: 10.1371/journal.pone.0184597. eCollection 2017.
8
Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical Trial.索拉非尼联合 TACE 与单纯 TACE 治疗复发性中期肝细胞癌患者的生存：随机临床试验。
JAMA Oncol. 2024 Aug 1;10(8):1047-1054. doi: 10.1001/jamaoncol.2024.1831.
9
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
10
A systematic overview of chemotherapy effects in colorectal cancer.结直肠癌化疗效果的系统综述。
Acta Oncol. 2001;40(2-3):282-308. doi: 10.1080/02841860151116367.

本文引用的文献

1
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.特瑞利木单抗联合度伐利尤单抗治疗不可切除肝细胞癌。
NEJM Evid. 2022 Aug;1(8):EVIDoa2100070. doi: 10.1056/EVIDoa2100070. Epub 2022 Jun 6.
2
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).奥沙利铂联合氟尿嘧啶与索拉非尼治疗晚期肝细胞癌的动脉化疗：一项生物分子探索性、随机、III 期试验（FOHAIC-1）。
J Clin Oncol. 2022 Feb 10;40(5):468-480. doi: 10.1200/JCO.21.01963. Epub 2021 Dec 14.
3
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update.
日本肝细胞癌的管理：2021年更新版日本肝脏学会共识声明与建议
Liver Cancer. 2021 Jun;10(3):181-223. doi: 10.1159/000514174. Epub 2021 May 19.
4
Hepatocellular carcinoma.肝细胞癌。
Nat Rev Dis Primers. 2021 Jan 21;7(1):6. doi: 10.1038/s41572-020-00240-3.
5
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).肝细胞癌诊疗指南（2019年版）
Liver Cancer. 2020 Dec;9(6):682-720. doi: 10.1159/000509424. Epub 2020 Nov 11.
6
Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.肝动脉灌注化疗与索拉非尼治疗晚期肝细胞癌的疗效比较
Liver Cancer. 2020 Sep;9(5):583-595. doi: 10.1159/000508724. Epub 2020 Jul 24.
7
Hepatic arterial infusion of oxaliplatin plus raltitrexed in patients with intermediate and advanced stage hepatocellular carcinoma: A phase II, single-arm, prospective study.奥沙利铂联合雷替曲塞经肝动脉灌注治疗中晚期肝细胞癌的Ⅱ期单臂前瞻性研究。
Eur J Cancer. 2020 Jul;134:90-98. doi: 10.1016/j.ejca.2020.03.032. Epub 2020 Jun 1.
8
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
9
Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis.索拉非尼与肝动脉灌注化疗治疗伴门静脉癌栓的晚期肝细胞癌的比较。
Gut Liver. 2021 Mar 15;15(2):284-294. doi: 10.5009/gnl19367.
10
Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II study.常规化疗失败后不可切除的结直肠癌肝转移患者接受雷替曲塞和奥沙利铂肝动脉化疗与标准化疗的比较（HEARTO）：一项随机 II 期研究。
J Cancer Res Clin Oncol. 2019 Sep;145(9):2357-2363. doi: 10.1007/s00432-019-02970-8. Epub 2019 Jul 4.